HCPCS Level II · Drugs administered other than oral method
J0688Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0688
J0688 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg.
It was added to HCPCS effective 01/01/2024, and its current record took effect 01/01/2025.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Inj cefazolin sodium, hikma
- Date added
- 01/01/2024
- Action effective
- 01/01/2025
- BETOS
- O1E
Related J06xx codes
- J0600Injection, edetate calcium disodium, up to 1000 mg
- J0601Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0602Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
- J0603Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0604Cinacalcet, oral, 1 mg, (for esrd on dialysis)
- J0605Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
- J0606Injection, etelcalcetide, 0.1 mg
- J0607Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
- J0608Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
- J0609Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
- J0612Injection, calcium gluconate, not otherwise specified, 10 mg
- J0613Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg
Common questions about J0688
Is HCPCS J0688 still valid?
- Yes. J0688 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J0688?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.